NCT05321810View on ClinicalTrials.gov

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

CompletedOBSERVATIONAL
Enrollment

193,565

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

April 15, 2022

Study Completion Date

April 15, 2022

Conditions
Non-valvular Atrial Fibrillation
Interventions
DRUG

Apixaban

This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.

DRUG

Warfarin

This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.

Trial Locations (1)

Unknown

Pfizer, Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY